From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

EXPOSE: Dispensa Interims, a string of accounting howlers, the end game will be 0p

By Tom Winnifrith | Friday 1 December 2023


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Yesterday, Dispensa (DISP), the Standard listed joke formerly known as Zamaz (ZAMZ), a company only Andrew Monk of VSA Capital (VSA) seems prepared to act for, served up its second set of interim results, covering the six months ended 31 August 2023. As you’d expect with a Monk client and a company controlled by Dominic White of the Supply@ME Capital (SYME) fraud infamy, the numbers are a joke and riddled with schoolboy errors. Does Monk care any more about attaching his name to such piffle and associating himself with such low life? Or is he just completely desperate for any business he can get?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:56:49